SCHEMBL1480968

SCHEMBL1480968

COc1ccc(/C=C/c2nc(-c3ccc(Cl)cc3Cl)c[nH]2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.45
BACE1 P56817 1/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
HCRTR1 O43613 1/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45
CASP3 P42574 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
AR P10275 1/20 0.43
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480971 1.00 ACHE (0.45) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1483101 0.91 KIT (0.41) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1483102 0.91 KIT (0.41) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1481654 0.88 AGPAT2 (0.39) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1481657 0.88 AGPAT2 (0.39) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL6527253 0.87 KIT (0.38) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL6531518 0.87 KIT (0.38) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1483642 0.86 RELA (0.41) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1483641 0.86 RELA (0.41) ACHEBACE1MAPTHPGDSMN1; SMN2
SCHEMBL1480451 0.86 RELA (0.46) ACHEBACE1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ ACHE 2761/4885BACE1 4200/4885MAPT 3558/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ ACHE 2761/4885BACE1 4200/4885MAPT 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.